In Q4 2025, Pacira generated total revenues of 196873000 and GAAP net income of 1637000, as higher operating expenses offset revenue growth, while adjusted EBITDA was 38709000.

Pacira BioSciences reported total revenues of $181.1 million for the second quarter of 2025, a slight increase from the previous year. The company experienced a net loss of $4.8 million, or $0.11 per share, but achieved a non-GAAP net income of $36.0 million, or $0.74 per diluted share. Key product sales showed growth for EXPAREL and ZILRETTA, while iovera° sales remained stable. The company also highlighted strategic advancements including a new revolving credit facility and expanded ZILRETTA promotional efforts.

Pacira BioSciences reported total revenues of $168.9 million for the first quarter of 2025, a slight increase from the prior year. Net income was $4.8 million, or $0.10 per share, compared to $9.0 million, or $0.19 per share, in the first quarter of 2024. Adjusted EBITDA was $44.1 million.

Pacira BioSciences, Inc. reported a 3% increase in total revenues for the fourth quarter of 2024, reaching $187.3 million, compared to $181.2 million in the same period last year. The company's GAAP net income for the quarter was $16.0 million, or $0.35 per basic share. Full-year revenues for 2024 were $701.0 million, a 4% increase from 2023.

Pacira BioSciences reported third quarter 2024 financial results with total revenues of $168.6 million. Net loss was $143.5 million, or $3.11 per share. Adjusted EBITDA was $54.7 million. The company is reiterating its full-year 2024 financial guidance.

Pacira BioSciences reported a total revenue of $178.0 million for Q2 2024, with net income reaching $18.9 million, or $0.39 per share (diluted). The company is focused on maximizing the benefit of separate EXPAREL reimbursement for outpatient procedures with the implementation of NOPAIN in January 2025.

Pacira BioSciences reported total revenues of $167.1 million for Q1 2024, with net income of $9.0 million, or $0.19 per share. The company also announced a new $150 million share repurchase program.

Pacira BioSciences reported Q4 2023 financial results, featuring a 5% increase in total revenues to $181.2 million and a GAAP net income of $24.9 million, or $0.54 per basic share. The company also reported an adjusted EBITDA of $65.4 million for the quarter.

Pacira BioSciences reported third-quarter revenue of $163.9 million and net income of $10.9 million, or $0.23 per share. Adjusted EBITDA was $52.9 million. The company revised its full-year EXPAREL guidance to $535 million to $540 million.

Pacira BioSciences reported total revenues of $169.5 million for Q2 2023, with a net income of $25.8 million, or $0.51 per share (diluted). EXPAREL net product sales were $135.1 million, ZILRETTA net product sales were $29.3 million, and iovera° net product sales were $4.4 million.

Pacira BioSciences reported total revenues of $160.3 million in the first quarter of 2023. EXPAREL net product sales were $130.4 million, ZILRETTA net product sales were $24.3 million, and iovera° net product sales were $4.0 million. The company reported a GAAP net loss of $19.5 million, or $0.43 per share, and an adjusted EBITDA of $41.9 million.

Pacira BioSciences reported a revenue of $172.0 million for Q4 2022, an 8% increase compared to Q4 2021. The company's GAAP net loss was $10.1 million, or $0.22 per basic and diluted share, while adjusted EBITDA was $58.8 million.

Pacira BioSciences reported a strong third quarter with total revenues of $167.5 million, a 31% increase compared to the third quarter of 2021. The company reported a net loss of $0.7 million, or $(0.02) per share, and an adjusted EBITDA of $55.2 million.

Pacira BioSciences reported preliminary net product sales of $50.2 million for July 2022. EXPAREL sales grew, and ZILRETTA continued to perform well in its early growth stage. The company is not providing 2022 revenue or gross margin guidance at this time given the continued uncertainty around labor shortages, COVID-19, and the pace of recovery for the elective surgery market.

Pacira BioSciences reported preliminary unaudited net product sales for EXPAREL and iovera° for April 2022. EXPAREL net product sales were $44.8 million, while iovera° net product sales were $1.1 million.

Pacira BioSciences reported a 22% increase in total revenues for Q4 2021, reaching $159.2 million compared to $131.0 million in Q4 2020. EXPAREL net product sales increased by 12% to $139.9 million. The company experienced a GAAP net loss of $5.1 million, or $0.12 per share, but adjusted EBITDA increased by 61% to $69.3 million.

Pacira BioSciences reported preliminary unaudited net product sales for October 2021, with EXPAREL sales at $42.5 million and iovera° sales at $1.2 million. The company is confident in strong growth in the fourth quarter due to a reduction in pandemic-related challenges.

Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera° for July 2021, with EXPAREL average daily sales at 117% of July 2020. The company is confident in achieving its five-year goals of top-line growth and operating margins.

Pacira BioSciences reported preliminary unaudited net product sales of $44.6 million for April 2021, with EXPAREL contributing $43.1 million and iovera° contributing $1.5 million. EXPAREL average daily sales were 449% of April 2020.

Pacira BioSciences reported Q4 2020 financial results with total revenues of $131.0 million, a 7% increase over Q4 2019. GAAP net income was $14.5 million, or $0.33 per share (basic) and $0.32 (diluted). Adjusted EBITDA was $42.9 million, a 48% increase over the prior year.

Pacira BioSciences reported a 12% increase in total revenues, reaching $117.5 million, driven by EXPAREL net product sales which also increased by 12% to $113.7 million. The company achieved GAAP net income of $130.1 million, or $3.03 per share, and non-GAAP net income of $29.9 million, or $0.70 per share.

Pacira BioSciences reported a decrease in total revenues to $75.5 million and a GAAP net loss of $7.3 million for Q2 2020, impacted by the COVID-19 pandemic. However, EXPAREL sales showed recovery in June, and the company completed a financing that improved its financial foundation.

Pacira BioSciences reported a 16% increase in total revenues to $105.7 million for the first quarter of 2020, driven by growth in EXPAREL net product sales. The company achieved GAAP net income of $8.2 million, or $0.19 per share, compared to a net loss in the prior year. Due to the COVID-19 pandemic, the company has withdrawn its full-year 2020 financial guidance.

Pacira BioSciences, Inc. reported a 29% increase in total revenues for the fourth quarter of 2019, reaching $122.4 million, driven by a 24% increase in EXPAREL net product sales and iovera° net product sales of $3.2 million. The company's GAAP net loss was $4.9 million, or $0.12 per share, while non-GAAP net income was $23.8 million, or $0.56 per share. Pacira also provided full-year 2020 revenue guidance of between $485 million and $500 million.